Ropes & Gray: Client Novo Nordisk Signs Collaboration to Develop New Obesity Drugs
May 10, 2024
May 10, 2024
BOSTON, Massachusetts, May 10 -- Ropes and Gray, a law firm, issued the following news:
Ropes & Gray advised Novo Nordisk in a research collaboration agreement with Flagship Pioneering and Metaphone Biotechnologies, a company designing drugs by combining machine learning and molecular mimicry, to develop up to two next-generation therapeutics for the treatment of obesity. The transaction was announced on May 9.
Under the agreement, Novo Nordisk may pay up to $600 mi . . .
Ropes & Gray advised Novo Nordisk in a research collaboration agreement with Flagship Pioneering and Metaphone Biotechnologies, a company designing drugs by combining machine learning and molecular mimicry, to develop up to two next-generation therapeutics for the treatment of obesity. The transaction was announced on May 9.
Under the agreement, Novo Nordisk may pay up to $600 mi . . .